BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27121124)

  • 1. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
    Yamashita M; Wada H; Eguchi H; Ogawa H; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Umeshita K; Doki Y; Mori M
    Int J Oncol; 2016 Jul; 49(1):89-98. PubMed ID: 27121124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition.
    Sun ZP; Zhang J; Shi LH; Zhang XR; Duan Y; Xu WF; Dai G; Wang XJ
    Biomed Pharmacother; 2015 Dec; 76():65-72. PubMed ID: 26653552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
    Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
    BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells.
    Toshiyama R; Konno M; Eguchi H; Takemoto H; Noda T; Asai A; Koseki J; Haraguchi N; Ueda Y; Matsushita K; Asukai K; Ohashi T; Iwagami Y; Yamada D; Sakai D; Asaoka T; Kudo T; Kawamoto K; Gotoh K; Kobayashi S; Satoh T; Doki Y; Nishiyama N; Mori M; Ishii H
    Oncogene; 2019 Jan; 38(2):244-260. PubMed ID: 30089817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
    BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BC-02 eradicates liver cancer stem cells by upregulating the ROS-dependent DNA damage.
    Dou C; Fang C; Zhao Y; Fu X; Zhang Y; Zhu D; Wu H; Liu H; Zhang J; Xu W; Liu Z; Wang H; Li D; Wang X
    Int J Oncol; 2017 Dec; 51(6):1775-1784. PubMed ID: 29039459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Eltrombopag antitumor effect on hepatocellular carcinoma.
    Kurokawa T; Murata S; Zheng YW; Iwasaki K; Kohno K; Fukunaga K; Ohkohchi N
    Int J Oncol; 2015 Nov; 47(5):1696-702. PubMed ID: 26397763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
    Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
    Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
    Jilek JL; Tu MJ; Zhang C; Yu AM
    Drug Metab Dispos; 2020 Dec; 48(12):1257-1263. PubMed ID: 33051247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.
    Jiang Y; Li X; Hou J; Huang Y; Wang X; Jia Y; Wang Q; Xu W; Zhang J; Zhang Y
    Eur J Med Chem; 2018 Jan; 143():334-347. PubMed ID: 29202398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.
    Kim HM; Haraguchi N; Ishii H; Ohkuma M; Okano M; Mimori K; Eguchi H; Yamamoto H; Nagano H; Sekimoto M; Doki Y; Mori M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S539-48. PubMed ID: 21879266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q; Zhang S; Kang M; Dong R; Zhao J
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
    Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
    Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.